Losartan effectiveness in arterial hypertension patients (ELLA study)

Abstract

Aim. To analyze antihypertensive effectiveness and safety of angiotensin (AT1) receptor blocker losartan, as well as its combination with ACE inhibitor enalapril, in arterial hypertension (AH) patients.
Material and methods. This 12-week open, comparative, randomized, prospective study included 60 AH patients aged 30-65 years. Two parallel groups included 30 individuals each. Group I (intervention) received losaratan (Losap), 50 mg once per day; Group II (control) - enalapril, 20 mg once per day. If target blood pressure (BP) level, <140/90 mm Hg, was not achieved, Group I patients were administered a fixed combination of losartan (50 mg/d) + hydrochlorthiazide (12,5 mg/d) once per day; Group II patients received enalapril plus hydrochlorthiazide (12,5 mg/d) once per day. Without any effect 8 weeks later, losartan and enalapril doses were titrated again. BP, electrocardiogram, and microalbuminuria (MAU) dynamics was assessed.
Results. Target BP level was achieved in 76% Group I patients and in 73,3% of Group II participants. Percentage of individuals on combined therapy was 63,3% in Group I, and 66,7% in Group II. In moderate AH patients (n=50), systolic BP (SBP) normalized in 96% of Group I participants and in 72% of Group II individuals (р=0,015). MAU reduced significantly.
Conclusion. Losap and Losap plus facilitated target BP level achievement in patients with mild to moderate AH, effectively controlled SBP, demonstrated nephroprotective effects.